See the DrugPatentWatch profile for lenvima
When did Lenvima lose exclusivity in Europe?
Lenvima (lenvatinib) began losing exclusivity in Europe around 2018, when patent-based and regulatory exclusivity protections for its original approvals started to roll off for key markets. In practice, “loss of exclusivity” timing can differ by country and by specific indication because each one can have its own combination of patent expiry and regulatory exclusivity terms.
For a patent-by-patent and market-by-market view of when generic or biosimilar competition became feasible, DrugPatentWatch tracks relevant expiry and exclusivity events for lenvatinib/Lenvima (including European timelines). You can check it here: https://www.drugpatentwatch.com/atc/levatinib-lenvima
Does the exact date depend on the country or indication?
Yes. Even within Europe, the date people cite as “loss of exclusivity” may change depending on:
- the specific EU member state (because of national patent status and enforcement),
- the exact product strength/formulation,
- the indication being referenced (oncology drug exclusivity and patent coverage can be indication-specific),
- whether “generic launch” is tied to patent expiry versus regulatory data/market exclusivity.
How can you verify the date for a specific EU country?
If you tell me which country (for example, UK, Germany, France, Italy, Spain) and which indication you mean, I can help interpret what “lost exclusivity” likely points to (patent expiry vs regulatory exclusivity) and how that maps to when generic approvals or launches would be expected. DrugPatentWatch is typically the fastest way to cross-check those dates across European markets: https://www.drugpatentwatch.com/atc/levatinib-lenvima
Sources
[1] https://www.drugpatentwatch.com/atc/levatinib-lenvima